Jupiter Neurosciences, Inc. (JUNS)
NASDAQ: JUNS · Real-Time Price · USD
0.2310
-0.0111 (-4.58%)
At close: Jun 8, 2026, 4:00 PM EDT
0.2350
+0.0040 (1.73%)
After-hours: Jun 8, 2026, 7:59 PM EDT
Jupiter Neurosciences Employees
Jupiter Neurosciences had 5 employees as of December 31, 2025. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change (1Y)
1
Growth (1Y)
25.00%
Revenue / Employee
$8,090
Profits / Employee
-$1,835,598
Market Cap
10.03M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 1 | 25.00% |
| Dec 31, 2024 | 4 | 0 | - |
| Jun 30, 2024 | 4 | - | - |
| Mar 31, 2024 | 4 | - | - |
| Dec 31, 2023 | 4 | -1 | -20.00% |
| Sep 30, 2022 | 5 | 0 | - |
| Jun 30, 2022 | 5 | 0 | - |
| Mar 31, 2022 | 5 | 0 | - |
| Sep 30, 2021 | 5 | - | - |
| Jun 30, 2021 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| NextCure | 40 |
| HCW Biologics | 35 |
| Lunai Bioworks | 29 |
| BioCardia | 21 |
| SeaStar Medical Holding | 17 |
| Theriva Biologics | 16 |
| BioRestorative Therapies | 14 |
| Kiora Pharmaceuticals | 13 |
JUNS News
- 12 days ago - Jupiter Neurosciences commences patient enrollment in RESET trial - TheFly
- 12 days ago - Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease - GlobeNewsWire
- 13 days ago - D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering - Accesswire
- 18 days ago - Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering - GlobeNewsWire
- 19 days ago - Jupiter Neurosciences announces pricing of $2M registered direct offering - TheFly
- 19 days ago - Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering - GlobeNewsWire
- 19 days ago - Jupiter Neurosciences to acquire licensing rights to ALA-002 for $3.33M upfront - TheFly
- 19 days ago - Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech - GlobeNewsWire